Quality Chemical Industries Limited is expanding pharmaceutical production in Kampala, reinforcing Uganda’s effort to manufacture more essential medicines locally and reduce dependence on imports. The Uganda Investment Authority says the company has invested more than $60 million and is undertaking a further $51 million expansion for a second facility.
Located in Luzira Industrial Park, QCIL is one of the relatively few pharmaceutical manufacturers in sub-Saharan Africa operating with World Health Organization prequalification. That status is important because it indicates that specified products and manufacturing processes have met internationally recognised quality requirements.
The new facility is expected to add capacity for about one billion tablets each year and introduce injectable products. Increased production could strengthen regional supply of medicines, but the impact will depend on the product mix, regulatory approvals, procurement arrangements and affordability.
Local manufacturing became a more visible policy priority after global supply disruptions exposed the vulnerability of countries that rely heavily on imported medicines. A domestic plant cannot eliminate every risk, because manufacturers may still import active ingredients, packaging and equipment, but it can shorten some supply chains and improve responsiveness.
QCIL’s existing workforce is about 600 people, including 354 permanent employees and more than 200 contract workers, according to the authority. The expansion is expected to create over 500 additional skilled jobs, offering opportunities in production, quality assurance, engineering, laboratories, logistics and administration.
Pharmaceutical jobs require specialised training and strict procedures. Partnerships with universities and technical institutions can help build a pipeline of pharmacists, chemists, microbiologists, engineers and technicians. Continuous professional development is also necessary because manufacturing standards and technologies evolve.
QCIL’s products reach 14 countries and 31 markets, demonstrating that Ugandan manufacturing can serve customers beyond the domestic market. Regional exports can increase production scale and foreign-exchange earnings, although companies must navigate registration rules and procurement systems in each destination.
The economic case for pharmaceutical manufacturing extends beyond direct employment. Plants require packaging, maintenance, transport, utilities, professional services and laboratory supplies. Developing qualified local suppliers can multiply the benefits and reduce the proportion of each production cycle that depends on imports.
Technology transfer has been an important part of QCIL’s development. Effective transfer involves more than installing machinery. It requires documented processes, quality systems, staff competence, maintenance capability and the ability to troubleshoot production without permanent external dependence.
The planned production of injectables represents an important technical step. Sterile manufacturing demands rigorous control of contamination, facilities, equipment and personnel. Regulatory oversight will be essential to ensure that expansion in volume never compromises product quality.
Government procurement can influence the viability of local manufacturers. Predictable purchasing and timely payment can help plants plan production, but preference for local goods must remain consistent with quality, price and reliable supply. Patients and health programmes should not carry excessive costs to support industry.
Access to affordable finance, dependable electricity and efficient customs procedures also matters. Pharmaceutical inputs often have strict storage conditions and production schedules. Delays at borders or power disruptions can increase costs and threaten quality.
The broader public-health benefit will depend on whether locally made medicines reach the facilities and patients that need them. Manufacturing policy therefore needs coordination with health planning, the national medicines regulator, procurement agencies and distribution systems.
Environmental management should grow with production. Pharmaceutical facilities must control chemical handling, wastewater, rejected products and packaging waste. Strong compliance protects communities and strengthens confidence in the industry.
QCIL’s expansion is a significant vote of confidence in Uganda’s industrial base. It also offers a test of whether the country can combine investment promotion, rigorous regulation, export growth and affordable access to medicines.
Success should be measured with transparent indicators: the facility’s completion, products approved, production volumes, jobs created, local purchasing, export growth and medicine availability. These results will show whether capital investment translates into broad economic and health benefits.
If the expansion is delivered as planned, Uganda will gain manufacturing capacity in a strategically important sector and a stronger platform for regional pharmaceutical trade.
Source: Uganda Investment Authority, “Quality Chemical Industries: one of few WHO-compliant pharma manufacturers in sub-Saharan Africa,” https://ugandainvest.go.ug/quality-chemical-industries-one-of-few-who-compliant-pharma-in-sub-saharan-africa/.
